Ada POPOLO | FARMACOLOGIA CLINICA E IMMUNOFARMACOLOGIA

cod. 0760100067

FARMACOLOGIA CLINICA E IMMUNOFARMACOLOGIA

	0760100067
	DIPARTIMENTO DI FARMACIA
	EQF7
	PHARMACY
	2020/2021

PERCORSO COMUNE Cohort 2017/2018

	OBBLIGATORIO
	YEAR OF COURSE 4
	YEAR OF DIDACTIC SYSTEM 2016
	SECONDO SEMESTRE

TEACHING UNITS

	SSD	CFU	HOURS	ACTIVITY	TYPE OF ACTIVITY
1	FARMACOLOGIA CLINICA MODULO DI FARMACOLOGIA CLINICA E IMMUNOFARMACOLOGIA
	BIO/14	5	40	LESSONS	COMPULSORY SUBJECTS, CHARACTERISTIC OF THE CLASS
2	IMMUNOFARMACOLOGIA MODUOLO DI FARMACOLOGIA CLINICA E IMMUNOFARMACOLOGIA
	BIO/14	5	40	LESSONS	COMPULSORY SUBJECTS, CHARACTERISTIC OF THE CLASS

PROFESSORS

	ADA POPOLO1 T Curriculum
	SILVANA MORELLO2 Curriculum

	Objectives
	THE TEACHING AIMS TO PROVIDE STUDENTS WITH: • KNOWLEDGE AND UNDERSTANDING THE BASIC CONCEPTS OF KNOWLEDGE IN THE FIELD OF IMMUNOPHARMACOLOGY AND BIO-ACTIVE PRINCIPLES USED IN THERAPIES TO TREAT DISEASES AND DISEASE STATES AND DRUG-INDUCED ADVERSE EVENTS. THE COURSE ALSO INCLUDES SPECIFIC TOPICS IN THE FIELD OF NEW DRUGS TESTING. TO KNOW AND UNDERSTAND THE PRINCIPLES OF IMMUNOLOGY AND IMMUNOPATHOLOGY AS WELL AS OF THE DRUGS ABLE TO INTERFERE WITH IMMUNE AND INFLAMMATORY RESPONSES • APPLYING KNOWLEDGE AND UNDERSTANDING THE ABILITY TO APPLY THE KNOWLEDGE ACQUIRED IN PHARMACOLOGY/TOXICOLOGY, IN PROBLEMS THAT MAY OCCUR THERAPIES SUCH AS THE ASSESSMENT OF ADVERSE EVENTS FOR THERAPY SUSTAINABILITY, TO IDENTIFY PROBLEM SOLVING TAKING INTO ACCOUNT THE INTERDISCIPLINARITY THAT CHARACTERIZES THE PHARMACOLOGY. TO BE ABLE TO APPLY THE ACQUIRED KNOWLEDGE ABOUT DRUGS FOR THE MANAGEMENT OF HUMAN IMMUNOINFLAMMATORY PATHOLOGIES AS WELL AS THE EVALUATION OF INTERACTIONS AND ADVERSE REACTIONS • MAKING JUDGMENTS MAKING JUDGMENTS AND INTEGRATING KNOWLEDGE TO MANAGE THE COMPLEXITY OF THERAPY FOR INNOVATING PHARMACOLOGY. WITH REGARD TO THE PHARMACIST ROLE AS INTERFACE BETWEEN THE PHYSICIAN AND THE PATIENT, TO MAKE JUDGMENTS ON THE BASIS OF INCOMPLETE OR LIMITED INFORMATION, BUT THAT INCLUDE REFLECTING ON SOCIAL AND ETHICAL RESPONSIBILITIES LINKED TO THE APPLICATION OF THEIR KNOWLEDGE AND JUDGMENTS. TO BE ABLE TO COMBINE OLD AND NEW INFORMATION IN ORDER TO APPLY IMMUNOPHARMACOLOGICAL PROGRESS IN THERAPY • COMMUNICATION SKILLS THE ABILITY TO COMMUNICATE IN A CLEAR AND UNAMBIGUOUS CONCLUSIONS OF THEIR KNOWLEDGE AND JUDGMENT TO A SPECIALIST (HEALTH WORKERS) AND NON-SPECIALISTS (PATIENTS) OF ANY GRADE AND LEVEL OF EDUCATION. • LEARNING SKILLS LEARNING SKILLS IN A SELF-DIRECTED OR AUTONOMY THAT MAY HELP FOR CONTINUOUS UPDATING, A NECESSARY CONDITION FOR THE PERFORMANCE OF THE FUNCTIONS OF A PHARMACIST, THROUGH THE USE OF TEXTS, SCIENTIFIC PUBLICATIONS IN THE FIELD, THE MAIN DATABASES OF REGULATORY AGENCIES (EMA, FDA, AIFA, ETC.).

THE TEACHING AIMS TO PROVIDE STUDENTS WITH:
• KNOWLEDGE AND UNDERSTANDING
THE BASIC CONCEPTS OF KNOWLEDGE IN THE FIELD OF IMMUNOPHARMACOLOGY AND BIO-ACTIVE PRINCIPLES USED IN THERAPIES TO TREAT DISEASES AND DISEASE STATES AND DRUG-INDUCED ADVERSE EVENTS. THE COURSE ALSO INCLUDES SPECIFIC TOPICS IN THE FIELD OF NEW DRUGS TESTING. TO KNOW AND UNDERSTAND THE PRINCIPLES OF IMMUNOLOGY AND IMMUNOPATHOLOGY AS WELL AS OF THE DRUGS ABLE TO INTERFERE WITH IMMUNE AND INFLAMMATORY RESPONSES

• APPLYING KNOWLEDGE AND UNDERSTANDING
THE ABILITY TO APPLY THE KNOWLEDGE ACQUIRED IN PHARMACOLOGY/TOXICOLOGY, IN PROBLEMS THAT MAY OCCUR THERAPIES SUCH AS THE ASSESSMENT OF ADVERSE EVENTS FOR THERAPY SUSTAINABILITY, TO IDENTIFY PROBLEM SOLVING TAKING INTO ACCOUNT THE INTERDISCIPLINARITY THAT CHARACTERIZES THE PHARMACOLOGY. TO BE ABLE TO APPLY THE ACQUIRED KNOWLEDGE ABOUT DRUGS FOR THE MANAGEMENT OF HUMAN IMMUNOINFLAMMATORY PATHOLOGIES AS WELL AS THE EVALUATION OF INTERACTIONS AND ADVERSE REACTIONS

• MAKING JUDGMENTS
MAKING JUDGMENTS AND INTEGRATING KNOWLEDGE TO MANAGE THE COMPLEXITY OF THERAPY FOR INNOVATING PHARMACOLOGY. WITH REGARD TO THE PHARMACIST ROLE AS INTERFACE BETWEEN THE PHYSICIAN AND THE PATIENT, TO MAKE JUDGMENTS ON THE BASIS OF INCOMPLETE OR LIMITED INFORMATION, BUT THAT INCLUDE REFLECTING ON SOCIAL AND ETHICAL RESPONSIBILITIES LINKED TO THE APPLICATION OF THEIR KNOWLEDGE AND JUDGMENTS. TO BE ABLE TO COMBINE OLD AND NEW INFORMATION IN ORDER TO APPLY IMMUNOPHARMACOLOGICAL PROGRESS IN THERAPY

• COMMUNICATION SKILLS
THE ABILITY TO COMMUNICATE IN A CLEAR AND UNAMBIGUOUS CONCLUSIONS OF THEIR KNOWLEDGE AND JUDGMENT TO A SPECIALIST (HEALTH WORKERS) AND NON-SPECIALISTS (PATIENTS) OF ANY GRADE AND LEVEL OF EDUCATION.
• LEARNING SKILLS
LEARNING SKILLS IN A SELF-DIRECTED OR AUTONOMY THAT MAY HELP FOR CONTINUOUS UPDATING, A NECESSARY CONDITION FOR THE PERFORMANCE OF THE FUNCTIONS OF A PHARMACIST, THROUGH THE USE OF TEXTS, SCIENTIFIC PUBLICATIONS IN THE FIELD, THE MAIN DATABASES OF REGULATORY AGENCIES (EMA, FDA, AIFA, ETC.).

	Prerequisites
	FOR UNDERSTANDING OF THIS COURSE, IT IS IMPORTANT THE ACQUISITION OF THE FOLLOWING DISCIPLINES: ANATOMY, PHYSIOLOGY AND PATHOLOGY, PHARMACOLOGY AND PHARMACOTHERAPY, MOLECULAR BIOLOGY

	Contents
	IMMUNOPHARMACOLOGY: INNATE AND ACQUIRED IMMUNE RESPONSES (6 HOURS). IMMUNOSUPPRESSORS: GLUCOCORTICOIDS (4 HOURS), CALCINEURIN INHIBITORS (2 HOURS), SIROLIMUS, CYTOTOXIC DRUGS (2 HOURS), MONOCLONAL ANTIBODIES AND FUSION PROTEINS (6 HOURS). IMMUNOSTIMULANTS. IMMUNOTHERAPY OF MS (2 HOURS), AR (2 HOURS), ASTHMA (2 HOURS), PSORIASIS (2 HOURS), TUMORS (8 HOURS). VACCINES AND IMMUNOGLOBULINES (4 HOURS) PRE-CLINICAL TESTING: IN VITRO AND IN VIVO STUDIES; EVALUATION OF ACUTE, SUB-ACUTE AND CHRONIC TOXICITY OF NEW DRUGS (2 HOURS). CLINICAL TRIAL, GOOD CLINICAL PRACTICE (8 HOURS); PHARMACOVIGILANCE; ADVERSE DRUG REACTIONS. LEGAL AND ETHICAL ASPECTS OF CLINICAL TRIALS. MARKETING AUTHORIZATION (14 HOURS). RATIONAL USE OF DRUGS IN PREGNANCY (2 HOURS), IN CHILDREN (2 HOURS), IN ELDERLY (2 HOURS), IN PATIENTS WITH LIVER DISEASE (2 HOURS) OR KIDNEY FAILURE (2 HOURS).THERAPEUTIC DRUG MONITORING (8 HOURS).

Contents

IMMUNOPHARMACOLOGY:
INNATE AND ACQUIRED IMMUNE RESPONSES (6 HOURS). IMMUNOSUPPRESSORS: GLUCOCORTICOIDS (4 HOURS), CALCINEURIN INHIBITORS (2 HOURS), SIROLIMUS, CYTOTOXIC DRUGS (2 HOURS), MONOCLONAL ANTIBODIES AND FUSION PROTEINS (6 HOURS). IMMUNOSTIMULANTS. IMMUNOTHERAPY OF MS (2 HOURS), AR (2 HOURS), ASTHMA (2 HOURS), PSORIASIS (2 HOURS), TUMORS (8 HOURS).
VACCINES AND IMMUNOGLOBULINES (4 HOURS)

PRE-CLINICAL TESTING: IN VITRO AND IN VIVO STUDIES; EVALUATION OF ACUTE, SUB-ACUTE AND CHRONIC TOXICITY OF NEW DRUGS (2 HOURS). CLINICAL TRIAL, GOOD CLINICAL PRACTICE (8 HOURS); PHARMACOVIGILANCE; ADVERSE DRUG REACTIONS. LEGAL AND ETHICAL ASPECTS OF CLINICAL TRIALS. MARKETING AUTHORIZATION (14 HOURS). RATIONAL USE OF DRUGS IN PREGNANCY (2 HOURS), IN CHILDREN (2 HOURS), IN ELDERLY (2 HOURS), IN PATIENTS WITH LIVER DISEASE (2 HOURS) OR KIDNEY FAILURE (2 HOURS).THERAPEUTIC DRUG MONITORING (8 HOURS).

	Teaching Methods
	LECTURE

	Verification of learning
	ORAL EXAMINATION

	Texts
	TRATTATO DI FARMACOLOGIA, IDELSON-GNOCCHI. SECONDA EDIZIONE FARMACOLOGIA CLINICA. FUCCELLA L M, PERRUCA E, SIRTORI C. UTET FARMACOLOGIA E TERAPIA. AVERY, ZANICHELLI, 2000. FARMACOLOGIA, GOVONI, CASA EDITRICE AMBROSIANA IMMUNOLOGIA CELLULARE E MOLECOLARE, ABBAS KA (PICCIN, PADOVA, IV ED. IT. 2000) IMMUNOBIOLOGIA, JANEWAY CA (PICCIN, III ED. IT. 2007)

	More Information
	ITALIAN TEACHING AT THE DEPARTMENT OF PHARMACY

BETA VERSION Data source ESSE3 [Ultima Sincronizzazione: 2022-05-23]

Ada POPOLO | FARMACOLOGIA CLINICA E IMMUNOFARMACOLOGIA